[Hydrogen effect on the mechanisms of mucosal immunity in patients with COVID-19]
Svitich OA, Baranova IA, Kryukova NO, Poddubikov AV, Vinnitskaya AB, Abramova ND, Zakharova VV, Shogenova LV, Kostinov MP, Chuchalin AG. · Terapevticheskii arkhiv. 2022; pp. 372–377.
Study at a glance
Some nose and throat immune markers changed over ten days in health workers after COVID-19, while several blood and mucosal measures did not. Allocation was not described as randomized. These laboratory changes do not establish infection prevention or improvement in post-COVID symptoms.
Human
60 health workers after COVID-19; 30 received hydrogen alongside rehabilitation and 30 standard rehabilitation.
SUISONIA (Japan) nasal-cannula hydrogen exposure for 90 minutes daily over 10 days, alongside rehabilitation. · H₂ concentration and purity were not reported. The article’s active-hydrogen terminology does not establish atomic hydrogen or a measured molecular dose.
90 minutes daily for 10 days; immune measurements on days 1 and 10.
Nasal granulocyte phagocytosis rose 2.5-fold from baseline (P = 0.000189) and was 1.1-fold above control (P = 0.047410). Pharyngeal monocyte phagocytosis rose 2.8-fold from baseline (P = 0.041103), but did not differ significantly from control. Blood granulocyte/monocyte and pharyngeal granulocyte measures were unchanged. Nasal secretory IgA rose 2.9-fold from baseline, while pharyngeal secretory IgA halved. These surrogate changes do not establish infection prevention or symptom improvement.
Small nonrandomized study with sparse allocation/attrition reporting, multiple surrogate analyses and unquantified gas exposure. No established clinical improvement, infection-prevention effect or independent molecular-exposure validation.
What kind of evidence is this?
Human
Controlled post-COVID rehabilitation study; randomization and blinding were not described.
Влияние водорода на механизмы мукозального иммунитета у пациентов, перенесших заболевание COVID-19
Immune and inflammatory conditions
Inhaled H₂
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
60 health workers after COVID-19; 30 received hydrogen alongside rehabilitation and 30 standard rehabilitation.
60 participants, 30 per group. Allocation and attrition accounting were sparse; a separate analyzed denominator was not clearly established.
90 minutes daily for 10 days; immune measurements on days 1 and 10.
SUISONIA (Japan) nasal-cannula hydrogen exposure for 90 minutes daily over 10 days, alongside rehabilitation.
Generator gas described as hydrogen; the actual composition, purity and molecular exposure were not quantified.
H₂ concentration and purity were not reported. The article’s active-hydrogen terminology does not establish atomic hydrogen or a measured molecular dose.
Gas flow was not reported in the checked main article.
Oxygen co-delivery and inspired fraction were not reported.
Standard rehabilitation without the added hydrogen exposure.
Outcomes and reported result
Phagocytosis and mucosal immunoglobulins; no prespecified primary-outcome hierarchy reported.
Nasal granulocyte phagocytosis rose 2.5-fold from baseline (P = 0.000189) and was 1.1-fold above control (P = 0.047410). Pharyngeal monocyte phagocytosis rose 2.8-fold from baseline (P = 0.041103), but did not differ significantly from control. Blood granulocyte/monocyte and pharyngeal granulocyte measures were unchanged. Nasal secretory IgA rose 2.9-fold from baseline, while pharyngeal secretory IgA halved. These surrogate changes do not establish infection prevention or symptom improvement.
The available main full text was reviewed for methods, results, limitations and declarations. Uncertainties, supplementary-source limits and conflicting findings are stated in this record.
Systematic adverse-event assessment was not reported.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Small nonrandomized study with sparse allocation/attrition reporting, multiple surrogate analyses and unquantified gas exposure. No established clinical improvement, infection-prevention effect or independent molecular-exposure validation.
Short-term immune-marker observations in health workers after COVID-19, not proven clinical rehabilitation or infection-prevention benefit.
No external funding declared.
No competing interests declared.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 36286901 · DOI: 10.26442/00403660.2022.03.201398
Complete six-page Russian-language publisher article, pages 372–377, including English abstract, eight figures, disclosures and references.
AI-assisted editorial review of the available main full text, 29 October 2026. No independent clinical or statistical assessment has been performed.
Pages 372–373: abstracts and introduction; page 374: Methods, exposure, samples and statistics; pages 374–376: Results/Figures 1–8; pages 376–377: Discussion, funding, conflicts and references.
AI-assisted editorial review of the available main full text, 29 October 2026. Complete six-page Russian-language publisher article, pages 372–377, including English abstract, eight figures, disclosures and references.
Written informed consent reported; no trial-registration identifier reported.
29 October 2026
Help people check the facts before they buy.
Hydrogenology keeps 692 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.